Cargando…
Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts
AIM: ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine – composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors. METHODS: In this double-blinded, randomized, Phase II study bevacizumab-naive patients with recurr...
Autores principales: | Bota, Daniela A, Chung, Jinah, Dandekar, Manisha, Carrillo, Jose A, Kong, Xiao-Tang, Fu, Beverly D, Hsu, Frank PK, Schönthal, Axel H, Hofman, Florence M, Chen, Thomas C, Zidovetzki, Raphael, Pretto, Chrystel, Strik, Ankie, Schijns, Virgil EJC, Stathopoulos, Apostolos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200061/ https://www.ncbi.nlm.nih.gov/pubmed/30157683 http://dx.doi.org/10.2217/cns-2018-0009 |
Ejemplares similares
-
Therapeutic Immunization against Glioblastoma
por: Schijns, Virgil E. J. C., et al.
Publicado: (2018) -
First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity
por: Schijns, Virgil E.J.C., et al.
Publicado: (2015) -
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide
por: Bota, Daniela A., et al.
Publicado: (2022) -
Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation
por: Stathopoulos, Apostolis, et al.
Publicado: (2012) -
Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
por: Gong, Hongyu, et al.
Publicado: (2023)